Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SKYE Stock Forecast 2025-2026
$1.82
Current Price
$56.06M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SKYE Price Targets
+1,057.0%
To High Target of $21.00
+726.4%
To Median Target of $15.00
+423.4%
To Low Target of $9.50
SKYE Price Momentum
-8.5%
1 Week Change
+29.1%
1 Month Change
-83.9%
1 Year Change
-35.7%
Year-to-Date Change
-86.5%
From 52W High of $13.44
+59.2%
From 52W Low of $1.14
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Skye Bioscience (SKYE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SKYE and similar high-potential opportunities.
Latest SKYE Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SKYE has a bullish consensus with a median price target of $15.00 (ranging from $9.50 to $21.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $1.82, the median forecast implies a 726.4% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kristen Kluska at Cantor Fitzgerald, projecting a 1,057.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SKYE Analyst Ratings
7
Buy
0
Hold
0
Sell
SKYE Price Target Range
Low
$9.50
Average
$15.00
High
$21.00
Current: $1.82
Latest SKYE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SKYE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Craig-Hallum | Albert Lowe | Buy | Maintains | $14.00 |
| Mar 21, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $15.00 |
| Feb 28, 2025 | William Blair | Andy Hsieh | Outperform | Initiates | $0.00 |
| Sep 30, 2024 | Scotiabank | George Farmer | Sector Outperform | Initiates | $20.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Sep 20, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $20.00 |
| Sep 10, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $15.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Sep 6, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Aug 27, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jul 9, 2024 | Craig-Hallum | Albert Lowe | Buy | Initiates | $18.00 |
| Jul 1, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jun 18, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| Jun 17, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $14.00 |
| May 23, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $21.00 |
| Apr 12, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $25.00 |
| Mar 14, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $20.00 |
| Feb 5, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Initiates | $12.00 |
Skye Bioscience Inc. (SKYE) Competitors
The following stocks are similar to Skye Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SKYE
Skye Bioscience
mkt cap
56.06M
Skye Bioscience Inc. (SKYE) Financial Data
Skye Bioscience Inc. has a market capitalization of $56.06M with a P/E ratio of 3.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -80.5%.
Valuation Metrics
Market Cap
$56.06M
Enterprise Value
$-12,515,692
P/E Ratio
3.6x
PEG Ratio
-1.6x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+121.7%
Current Ratio
16.3x
Debt/Equity
0.7x
ROE
-80.5%
ROA
-44.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Skye Bioscience Inc. (SKYE) Business Model
About Skye Bioscience Inc.
What They Do
Develops cannabinoid-based pharmaceuticals for eye diseases.
Business Model
Skye Bioscience develops novel pharmaceuticals that integrate cannabinoids to treat various diseases, particularly in ophthalmology. The company generates revenue by advancing its key product candidates, which focus on managing eye conditions like glaucoma, addressing significant unmet medical needs in the market.
Additional Information
The company operates in the biotechnology and healthcare sectors, leveraging the growing interest in cannabinoid-derived treatments. As regulatory environments evolve, Skye Bioscience plays a crucial role in advancing medical science and exploring new therapeutic applications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Mr. Punit S. Dhillon B.A.
Country
United States
IPO Year
2021
Website
skyebioscience.comSkye Bioscience Inc. (SKYE) Latest News & Analysis
Latest News
Quick Summary
Skye Bioscience, Inc. (NASDAQ:SKYE) will hold its Q1 2025 earnings conference call on May 9, 2025, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters
The earnings conference call provides insights into Skye Bioscience's financial performance and strategic direction, influencing investor sentiment and potential stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience, Inc. (NASDAQ: SKYE) reported Q1 2025 financial results and highlighted achievements in developing treatments for obesity and related conditions.
Why It Matters
Skye Bioscience's financial results and milestones signal progress in developing treatments for obesity, potentially impacting stock value and market confidence in biotech innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience, Inc. (Nasdaq: SKYE) will hold a conference call on May 8, 2025, at 1:30 p.m. PT to discuss its Q1 2025 financial results, with a press release issued post-market.
Why It Matters
Skye Bioscience's upcoming earnings call may reveal key financial performance and strategic insights, impacting stock valuation and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience (Nasdaq: SKYE) will present at the Citizens Life Sciences Conference on May 8 and participate in 1x1 meetings at the Craig-Hallum Conference on May 28, plus a poster presentation at the European Congress on Obesity on May 13.
Why It Matters
Skye Bioscience's participation in major healthcare conferences highlights its commitment to innovation in obesity treatment, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience, Inc. granted a non-qualified stock option for 19,000 shares to a new employee on April 23, 2025, as part of its 2024 Inducement Equity Incentive Plan.
Why It Matters
The granting of stock options indicates Skye Bioscience's commitment to attracting talent, which can drive innovation and growth, potentially impacting future stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Skye Bioscience (Nasdaq: SKYE) will hold 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17 in Boston, focusing on therapies for obesity and metabolic disorders.
Why It Matters
Skye Bioscience's participation in the Piper Sandler Symposium highlights its focus on innovative therapies, potentially attracting investor interest and impacting stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SKYE Stock
What is Skye Bioscience Inc.'s (SKYE) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Skye Bioscience Inc. (SKYE) has a median price target of $15.00. The highest price target is $21.00 and the lowest is $9.50.
Is SKYE stock a good investment in 2025?
According to current analyst ratings, SKYE has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SKYE stock?
Wall Street analysts predict SKYE stock could reach $15.00 in the next 12 months. This represents a 726.4% increase from the current price of $1.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Skye Bioscience Inc.'s business model?
Skye Bioscience develops novel pharmaceuticals that integrate cannabinoids to treat various diseases, particularly in ophthalmology. The company generates revenue by advancing its key product candidates, which focus on managing eye conditions like glaucoma, addressing significant unmet medical needs in the market.
What is the highest forecasted price for SKYE Skye Bioscience Inc.?
The highest price target for SKYE is $21.00 from Kristen Kluska at Cantor Fitzgerald, which represents a 1,057.0% increase from the current price of $1.82.
What is the lowest forecasted price for SKYE Skye Bioscience Inc.?
The lowest price target for SKYE is $9.50 from at , which represents a 423.4% increase from the current price of $1.82.
What is the overall SKYE consensus from analysts for Skye Bioscience Inc.?
The overall analyst consensus for SKYE is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are SKYE stock price projections?
Stock price projections, including those for Skye Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 5:38 PM UTC